Its use in multiple myeloma was attributed to the immunomodulatory and anti-angiogenic activity which downregulates the expression of TNF-α and IL-6 by the stromal cells in the bone marrow, thereby inhibiting the proliferation of multiple myeloma cells (Holstein and McCarthy 2017). Here, IL6 is linked to AL amyloidosis.